Shares of Indaptus Therapeutics tumbled another 14% to $1.75 on Tuesday, extending a punishing slide that has now erased roughly a third of the stock's value from its recent high of $2.77 just five days ago — all without a single piece of new company news to explain the selling. INDP Sheds a Third of Its Value in Five Days With Zero News — Can a Five-Employee Biotech Survive the Hangover?

Shares of Indaptus Therapeutics cratered another 14% to $1.75 on Tuesday, deepening a sell-off that has now wiped out roughly 37% from the stock's $2.77 close last Thursday. No new clinical data, no regulatory filing, no deal — just investors rushing for the exits after a speculative run-up collided with thin liquidity and a looming financial deadline.

  • Today Is the Day the Bills Come Due. Indaptus's convertible notes — carrying a 6% annual interest rate — mature today, July 28, 2026.

The company raised $5.7 million in total gross proceeds through those notes.

Upon conversion, noteholders receive shares at 80% of the average closing price over the prior five trading days, capped at $11.20 per share. That 20% discount means heavy dilution — more shares flooding into a stock already under selling pressure — and the recent price collapse makes the math worse for existing shareholders.

  • Five Employees, Zero Revenue, and a Cash Crunch. Indaptus has just five employees.

Its trailing twelve-month revenue is $0, and it posted a net loss of roughly $3.1 million.

The company previously warned that its cash would support operations only into the first quarter of 2026. Even after the convertible-note raise, the runway is razor-thin for a firm burning through R&D dollars with no product sales in sight.

  • The Drug Story Is Still Early and Unproven. In its Phase 1 trial, a single cancer patient with liver metastases achieved a partial response on the drug alone but subsequently progressed and discontinued.

In the combination arm with a PD-1 inhibitor, seven patients have been dosed so far. That is an extremely thin dataset to justify a market cap that recently exceeded $300 million — a staggering number for a pre-revenue company with preliminary safety data.

  • A Volatile Stock With a Massive Range Tells Its Own Story. Over the past year, INDP has swung between a 52-week low of $0.92 and a high of $10.91. That kind of range — more than 10-to-1 — signals a stock driven less by fundamentals than by speculative momentum and short squeezes. Today's slide reinforces that once buying enthusiasm fades, gravity returns fast.

The bottom line: With notes converting today, negligible clinical evidence, and no revenue runway, shareholders face dilution risk in the near term and existential funding risk beyond it.